The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
The Food and Drug Administration approved a new type of nonopioid painkiller, Journaxv, or suzetrigine, drugmaker Vertex ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to ...
Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...